USPTO serial 79353016
VISCOFAN FIBERCOLL-FLEX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 10, 2024
- Examiner
- TWOHIG, SHANNON MARIE
- Law office
- TMO LAW OFFICE 121
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with VISCOFAN FIBERCOLL-FLEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Douglas A. Miro
Douglas A. Miro Amster, Rothstein & Ebenstein LLP405 Lexington AvenueNew York, NY 10174United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological materials or preparations for 3D printers, namely, bioinks, bioprinting kits comprised of collagen, biological printed tissues other than for medical or veterinary purposes; hydrogels for cell culture not for medical or veterinary purposes; hydrogels for cell growth not for medical or veterinary purposes; cell culture media other than for medical or veterinary use; nutritional agents for processing living cells other than for medical use, namely, cell culture media within a reservoir for growth factors; culture media for microbiology for laboratory use; reagents for scientific and medical research; synthetic peptides not for pharmaceutical purposes, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; synthetic peptide derivatives not for pharmaceutical purposes, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; cells other than for medical, veterinary or pharmaceutical use; cells or tissues in hydrogels other than for medical, veterinary or pharmaceutical use; biologically compatible polymers, specifically hydrogels used to produce polymer networks used in the manufacture of engineered living tissues for medical, scientific and non-scientific purposes, namely, tissue implants, organoids, tissue models; cell culture media for use in the biotechnological industry for laboratory use; cell culture media for use in non-medical research laboratories; biological preparations for use in cell culture, other than for medical and veterinary purposes; engineered living tissues and tissue arrays, namely, human and animal organs, connective tissue, epithelial tissue, muscular tissue and nervous tissue, and tissue arrays, for use in scientific and medical research; biologically compatible materials, specifically, hydrogels used to create polymeric networks used in the manufacture of living tissues for laboratory use; proteins in the form of raw materials for scientific and medical research | ACTIVE | — |
| 002 | Inks of biological origin for printers; inks of biological origin for 3D printers | ACTIVE | — |
| 005 | Hydrogels for medical, veterinary and pharmaceutical purposes for cellular biology applications; hydrogels for cell growth, cell growth and transplantation, assays based on cells, cancer cell research, regenerative medicine, stem cell growth and drug delivery for medical use; hydrogels for cell culture for medical, veterinary and pharmaceutical purposes; hydrogels for cell growth for medical, veterinary and pharmaceutical purposes; cell culture media for medical use; nutritional agents for processing living cells, namely, cell culture media growth factors contained within a reservoir; synthetic peptides for the treatment of degenerated hard and soft tissues; synthetic peptide derivativesfor the treatment of degenerated hard and soft tissues; cells for medical, veterinary and pharmaceutical use; cells or tissues in hydrogels for medical, veterinary or pharmaceutical use; pharmaceutical preparations for use in 3D bio-printing of tissues and organs; pharmaceutical preparations with other materials and ingredients for use in 3D bio-printing of tissues and organs; regenerative tissue being pharmaceutical preparations for hard and soft tissue regeneration; cells for medical use; allogeneic human tissue; living cells for medical use; implants containing living tissue; implantable living tissue materials for use in guided tissue regeneration; skin grafts; surgical implants formed by living tissue; surgical implants of living tissues derived from stem cells; transdermal patches for the creation of skin for prostheses and skin grafts; living tissue for transplants; engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, epithelial, muscular, and nervous tissues and organs, for medical purposes; biological molecules being implants comprising living tissue to assist in tissue engineering, namely, hard and soft tissue regeneration; hemostatic gel matrix preparations for wound treatment; natural biomaterials for the growth of bones, blood and tissues for medical purposes; pharmaceutical products for the regeneration of tissues, for the repair of tissues, for the treatment of tissues, whether human or animal, namely, 3D implants for hard and soft tissue regeneration combining bioinks and biological materials; pharmaceutical preparations for the treatment of diseases of bones, cartilages, blood vessels, nerve cell degeneration, tendon and ligament degeneration, retinal degeneration, kidney degeneration; soft tissue degenerations, for diseases with abnormal cell growth, namely, formulated bioinks for hard and soft tissue regeneration combining bioinks and biological materials with a pharmaceutical effect; natural biomaterial for bone filling; natural biomaterial for cartilage filling; biological tissue cultures for medical use; biological tissue cultures for medical purposes; biological tissue grafts; bone and skin biological tissues impregnated with oxygen lines for tissue constructs applicable for increasing the cell survival in tissue intended for subsequent implants; gene therapy products, namely, genetically modified tissues for the transplant thereof; implantable stents composed primarily of living tissue to maintain the structure of the tissue; natural biomaterial for bone and tissue growth for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by VISCOFAN, S.A.
- Other trademarks owned by VISCOFAN, S.A.
- Other trademarks owned by VISCOFAN, S.A.
- Other trademarks in Class 001
- Other trademarks in Class 002
- Other trademarks in Class 005
- Similar marks named VISCOFAN FIBERCOLL-FLEX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 14, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 20, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 19, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 10, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 10, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 10, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 1, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 25, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 25, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 11, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 5, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 17, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 9, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 9, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 9, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 8, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 20, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 20, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 1, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 29, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 29, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 29, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 20, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 20, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 20, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 17, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 22, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 22, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 1, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 28, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 23, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 25, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 21, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 20, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |